Fig. 2From: The 5-HT1F receptor agonist lasmiditan as a potential treatment of migraine attacks: a review of two placebo-controlled phase II trialsProportion of migraine patients with HR at 2 h after oral lasmiditan 50–400 mg (PBO placebo). *P < 0.05 [17]Back to article page